These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 8605054)

  • 1. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
    AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
    Bucher HC; Griffith L; Guyatt GH; Opravil M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
    N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
    Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
    Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
    Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
    Podzamczer D; Santín M; Jimenez J; Casanova A; Bolao F; Gudiol GR
    AIDS; 1993 Apr; 7(4):501-6. PubMed ID: 8507417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group.
    Rizzardi GP; Lazzarin A; Musicco M; Frigerio D; Maillard M; Lucchini M; Moroni M
    J Infect; 1996 Mar; 32(2):123-31. PubMed ID: 8708369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial.
    Murri R; Ammassari A; Pezzotti P; Cingolani A; De Luca A; Pallavicini F; Grillo R; Antinori A
    J Acquir Immune Defic Syndr; 2001 May; 27(1):49-55. PubMed ID: 11404520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
    Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.
    Carr A; Tindall B; Brew BJ; Marriott DJ; Harkness JL; Penny R; Cooper DA
    Ann Intern Med; 1992 Jul; 117(2):106-11. PubMed ID: 1351371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
    Payen MC; De Wit S; Sommereijns B; Clumeck N
    Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
    Podzamczer D; Salazar A; Jiménez J; Consiglio E; Santín M; Casanova A; Rufí G; Gudiol F
    Ann Intern Med; 1995 May; 122(10):755-61. PubMed ID: 7717598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
    May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J; Benfield T; Atzori C; Miller RF
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.
    Köppen S; Grünewald T; Jautzke G; Gottschalk J; Pohle HD; Ruf B
    Clin Investig; 1992 Jun; 70(6):508-12. PubMed ID: 1356529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.